Etienne Puymirat1, Tabassome Simon2, Guillaume Cayla3, Yves Cottin4, Meyer Elbaz5, Pierre Coste6, Gilles Lemesle7, Pascal Motreff8, Batric Popovic9, Khalife Khalife10, Jean-Noel Labèque11, Thibaut Perret12, Christophe Le Ray13, Laurent Orion14, Bernard Jouve15, Didier Blanchard16, Patrick Peycher17, Johanne Silvain18, Philippe Gabriel Steg19, Patrick Goldstein20, Pascal Guéret21, Loic Belle22, Nadia Aissaoui1, Jean Ferrières23, François Schiele24, Nicolas Danchin25. 1. Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Department of Cardiology; Université Paris-Descartes, Paris, France; INSERM U-970, France (E.P., N.A., N.D.). 2. AP-HP, Hôpital Saint Antoine, Department of Clinical Pharmacology and Unité de Recherche Clinique (URCEST), Paris, France; Université Pierre et Marie Curie (UPMC-Paris 06); INSERM U-698, France (T.S.). 3. Centre Hospitalier Universitaire de Nîmes, France (G.C.). 4. Centre Hospitalier Universitaire du Bocage, Dijon, France (Y.C.). 5. Toulouse University Hospital, Department of Cardiology, France (M.E.). 6. Hôpital Cardiologique Haut Levêque, CHU de Bordeaux, Pessac, France (P.C.). 7. Lille Regional University Hospital, Department of Cardiology, France (G.L.). 8. Department of Cardiology, University Hospital of Clermont-Ferrand, UMR 6284 Auvergne University, France (P.M.). 9. Département de cardiologie, CHU de Nancy, Vandoeuvre-lès-Nancy, France (B.P.). 10. Centre Hospitalier Régional de Metz-Thionville, Mets, France (K.K.). 11. Centre Hospitalier de la Côte Basque, Bayonne, France (J.-N.L.). 12. Department of cardiology, Centre Hospitalier St Joseph et St Luc, Lyon, France (T.P.). 13. Centre Hospitalier Bretagne Atlantique, Vannes, France (C.L.R.). 14. Department of Cardiology, Centre Hospitalier de Vendée, La Roche-sur-Yon, France (L.O.). 15. Hospital of Aix en Provence, Department of Cardiology, France (B.J.). 16. Clinique St Gatien, Tours, France (D.B.). 17. Clinique Axium Aix en Provence, France (P.P.). 18. Institut de Cardiologie, Centre Hospitalier Pitié-Salpêtrière, Paris, France (J.S.). 19. AP-HP, Hôpital Bichat, Paris, France; Université Paris-Diderot, Sorbonne Paris-Cité, France; INSERM U-698, 75018 Paris, France (P.G.S.). 20. Lille Regional University Hospital, Emergency Department, France (P. Goldstein). 21. University Hospital Henri Mondor, Department of Cardiology, Créteil, France (P. Guéret). 22. Department of Cardiology, Centre hospitalier Annecy Genevois, Epagny Metz-Tessy, France (L.B.). 23. Toulouse Rangueil University Hospital, Department of Cardiology; UMR1027, INSERM, France (J.F.). 24. University Hospital Jean Minjoz, Department of Cardiology, Besançon, France (F.S.). 25. Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Department of Cardiology; Université Paris-Descartes, Paris, France; INSERM U-970, France (E.P., N.A., N.D.). nicolasdanchin@yahoo.fr.
Abstract
BACKGROUND: ST-segment-elevation myocardial infarction (STEMI) and non-ST-segment-elevation myocardial infarction (NSTEMI) management has evolved considerably over the past 2 decades. Little information on mortality trends in the most recent years is available. We assessed trends in characteristics, treatments, and outcomes for acute myocardial infarction in France between 1995 and 2015. METHODS: We used data from 5 one-month registries, conducted 5 years apart, from 1995 to 2015, including 14 423 patients with acute myocardial infarction (59% STEMI) admitted to cardiac intensive care units in metropolitan France. RESULTS: From 1995 to 2015, mean age decreased from 66±14 to 63±14 years in patients with STEMI; it remained stable (68±14 years) in patients with NSTEMI, whereas diabetes mellitus, obesity, and hypertension increased. At the acute stage, intended primary percutaneous coronary intervention increased from 12% (1995) to 76% (2015) in patients with STEMI. In patients with NSTEMI, percutaneous coronary intervention ≤72 hours from admission increased from 9% (1995) to 60% (2015). Six-month mortality consistently decreased in patients with STEMI from 17.2% in 1995 to 6.9% in 2010 and 5.3% in 2015; it decreased from 17.2% to 6.9% in 2010 and 6.3% in 2015 in patients with NSTEMI. Mortality still decreased after 2010 in patients with STEMI without reperfusion therapy, whereas no further mortality gain was found in patients with STEMI with reperfusion therapy or in patients with NSTEMI, whether or not they were treated with percutaneous coronary intervention. CONCLUSIONS: Over the past 20 years, 6-month mortality after acute myocardial infarction has decreased considerably for patients with STEMI and NSTEMI. Mortality figures continued to decline in patients with STEMI until 2015, whereas mortality in patients with NSTEMI appears stable since 2010.
BACKGROUND: ST-segment-elevation myocardial infarction (STEMI) and non-ST-segment-elevation myocardial infarction (NSTEMI) management has evolved considerably over the past 2 decades. Little information on mortality trends in the most recent years is available. We assessed trends in characteristics, treatments, and outcomes for acute myocardial infarction in France between 1995 and 2015. METHODS: We used data from 5 one-month registries, conducted 5 years apart, from 1995 to 2015, including 14 423 patients with acute myocardial infarction (59% STEMI) admitted to cardiac intensive care units in metropolitan France. RESULTS: From 1995 to 2015, mean age decreased from 66±14 to 63±14 years in patients with STEMI; it remained stable (68±14 years) in patients with NSTEMI, whereas diabetes mellitus, obesity, and hypertension increased. At the acute stage, intended primary percutaneous coronary intervention increased from 12% (1995) to 76% (2015) in patients with STEMI. In patients with NSTEMI, percutaneous coronary intervention ≤72 hours from admission increased from 9% (1995) to 60% (2015). Six-month mortality consistently decreased in patients with STEMI from 17.2% in 1995 to 6.9% in 2010 and 5.3% in 2015; it decreased from 17.2% to 6.9% in 2010 and 6.3% in 2015 in patients with NSTEMI. Mortality still decreased after 2010 in patients with STEMI without reperfusion therapy, whereas no further mortality gain was found in patients with STEMI with reperfusion therapy or in patients with NSTEMI, whether or not they were treated with percutaneous coronary intervention. CONCLUSIONS: Over the past 20 years, 6-month mortality after acute myocardial infarction has decreased considerably for patients with STEMI and NSTEMI. Mortality figures continued to decline in patients with STEMI until 2015, whereas mortality in patients with NSTEMI appears stable since 2010.
Authors: Nabil Ghorayeb; Ricardo Stein; Daniel Jogaib Daher; Anderson Donelli da Silveira; Luiz Eduardo Fonteles Ritt; Daniel Fernando Pellegrino Dos Santos; Ana Paula Rennó Sierra; Artur Haddad Herdy; Claúdio Gil Soares de Araújo; Cléa Simone Sabino de Souza Colombo; Daniel Arkader Kopiler; Filipe Ferrari Ribeiro de Lacerda; José Kawazoe Lazzoli; Luciana Diniz Nagem Janot de Matos; Marcelo Bichels Leitão; Ricardo Contesini Francisco; Rodrigo Otávio Bougleux Alô; Sérgio Timerman; Tales de Carvalho; Thiago Ghorayeb Garcia Journal: Arq Bras Cardiol Date: 2019-03 Impact factor: 2.000
Authors: Rachel A Schmidt; Craig N Morrell; Frederick S Ling; Preya Simlote; Genaro Fernandez; David Q Rich; David Adler; Joe Gervase; Scott J Cameron Journal: Transl Res Date: 2017-12-02 Impact factor: 7.012
Authors: Eva Querdel; Marina Reinsch; Liesa Castro; Thomas Eschenhagen; Florian Weinberger; Deniz Köse; Andrea Bähr; Svenja Reich; Birgit Geertz; Bärbel Ulmer; Mirja Schulze; Marc D Lemoine; Tobias Krause; Marta Lemme; Jascha Sani; Aya Shibamiya; Tim Stüdemann; Maria Köhne; Constantin von Bibra; Nadja Hornaschewitz; Simon Pecha; Yusuf Nejahsie; Ingra Mannhardt; Torsten Christ; Hermann Reichenspurner; Arne Hansen; Nikolai Klymiuk; M Krane; C Kupatt Journal: Circulation Date: 2021-03-02 Impact factor: 29.690